XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY (Tables)
 6 Months Ended
Jun. 30, 2024
STOCKHOLDERS' EQUITY [Abstract]  
Warrants Outstanding The following table summarizes information about warrants outstanding for the six months ended June 30, 2024:

   
Shares
    
Weighted
Average
Exercise Price
  
Warrants outstanding at December 31, 2023
    
12,502,906
 
$
2.32
  
Expired
    
(34,800
)
  
$
7.50
  
Granted
    
-
 
$
-
  
Exercised
    
(9,345,756
)
  
$
2.38
  
Warrants outstanding at June 30, 2024
    
3,122,350
 
$
2.08
  
Schedule of Assumptions The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2024 and 2023:

   
Six Months Ended June 30,
  
   
2024
    
2023
  
Expected term
  
5.5 - 6.3 years
    
5.5 - 6.3 years
  
Volatility
  
66%
 
68%

Dividend yield
  
0.0
    
0.0
  
Risk-free interest rate
  
4.29-4.34%

 
4.20-4.24%

Schedule of Option Activity


A summary of the Company’s option activity under the Company’s equity incentive plans and related information is as follows:

   
Shares
    
Weighted
Average
Exercise Price
  
Options outstanding, vested and expected to vest at December 31, 2023
    
5,906,184
    
$
3.38
  
Forfeited
    
(15,702
)
  
$
1.94
  
Expired
    
(212,717
)
  
$
7.55
  
Granted
    
1,396,524
    
$
5.65
  
Exercised     (555,171 )   $ 2.76  
Options outstanding, vested and expected to vest at June 30, 2024
    
6,519,118
    
$
3.79
  
                 
Options exercisable
    
3,585,489
    
$
3.55
  
Schedule of Unvested RSU Activity A summary of the Company’s unvested RSU activity and related information is as follows:

   
Shares
    
Weighted
Average Grant
Date Fair Value
  
Balance at December 31, 2023
    
4,657,297
    
$
2.81
  
Granted
    
2,781,288
    
$
5.61
  
Vested
    
(1,386,350
)
  
$
2.52
  
Forfeited
    
(186,438
)
  
$
3.45
  
Balance at June 30, 2024
    
5,865,797
    
$
4.19
  
Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and six months ended June 30, 2024 and 2023 is as follows:
   
Three Months Ended June 30,
    
Six Months Ended June 30,
  
(in thousands)  
2024
    
2023
    
2024
    
2023
  
Research and development
  
$
24
    
$
9
    
$
41
    
$
15
  
Plasma center operating expenses
    
48
      
40
      
87
      
63
  
Selling, general and administrative
    
2,405
      
1,410
      
4,246
      
2,388
  
Cost of product revenue
    
386
      
178
      
630
      
281
  
Total stock-based compensation expense
  
$
2,863
    
$
1,637
    
$
5,004
    
$
2,747